Barry D. Kerr

641 total citations
11 papers, 532 citations indexed

About

Barry D. Kerr is a scholar working on Endocrinology, Diabetes and Metabolism, Cellular and Molecular Neuroscience and Surgery. According to data from OpenAlex, Barry D. Kerr has authored 11 papers receiving a total of 532 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Cellular and Molecular Neuroscience and 6 papers in Surgery. Recurrent topics in Barry D. Kerr's work include Diabetes Treatment and Management (11 papers), Neuropeptides and Animal Physiology (9 papers) and Pancreatic function and diabetes (6 papers). Barry D. Kerr is often cited by papers focused on Diabetes Treatment and Management (11 papers), Neuropeptides and Animal Physiology (9 papers) and Pancreatic function and diabetes (6 papers). Barry D. Kerr collaborates with scholars based in United Kingdom. Barry D. Kerr's co-authors include Peter R. Flatt, Victor A. Gault, Christian Hölscher, Patrick Harriott, David W. Porter, Nigel Irwin, Srividya Vasu, Finbarr O’Harte and Clifford J. Bailey and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Diabetologia and Biochemical Pharmacology.

In The Last Decade

Barry D. Kerr

10 papers receiving 526 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barry D. Kerr United Kingdom 10 379 218 177 171 129 11 532
Peter S. Griffin United States 6 243 0.6× 138 0.6× 185 1.0× 103 0.6× 157 1.2× 6 572
Todd M. Suter United States 9 270 0.7× 119 0.5× 258 1.5× 157 0.9× 283 2.2× 12 740
Carrie Wittmer United States 12 397 1.0× 192 0.9× 199 1.1× 134 0.8× 306 2.4× 12 951
Guido Haschke Germany 9 174 0.5× 108 0.5× 134 0.8× 52 0.3× 116 0.9× 10 407
Holly E. Bates Canada 10 207 0.5× 195 0.9× 160 0.9× 46 0.3× 192 1.5× 15 554
Margaret Lautz United States 14 288 0.8× 301 1.4× 195 1.1× 33 0.2× 188 1.5× 22 604
J.H. Moltz United States 9 199 0.5× 202 0.9× 154 0.9× 204 1.2× 82 0.6× 14 664
M. Ghiglione Spain 11 212 0.6× 186 0.9× 138 0.8× 142 0.8× 74 0.6× 26 433
Junhui Tan Canada 13 250 0.7× 88 0.4× 144 0.8× 37 0.2× 54 0.4× 14 526
Sechiko Suga Japan 14 103 0.3× 208 1.0× 262 1.5× 95 0.6× 68 0.5× 31 481

Countries citing papers authored by Barry D. Kerr

Since Specialization
Citations

This map shows the geographic impact of Barry D. Kerr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry D. Kerr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry D. Kerr more than expected).

Fields of papers citing papers by Barry D. Kerr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry D. Kerr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry D. Kerr. The network helps show where Barry D. Kerr may publish in the future.

Co-authorship network of co-authors of Barry D. Kerr

This figure shows the co-authorship network connecting the top 25 collaborators of Barry D. Kerr. A scholar is included among the top collaborators of Barry D. Kerr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry D. Kerr. Barry D. Kerr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Kerr, Barry D., et al.. (2013). A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochemical Pharmacology. 85(11). 1655–1662. 63 indexed citations
3.
Gault, Victor A., Barry D. Kerr, Patrick Harriott, & Peter R. Flatt. (2011). Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clinical Science. 121(3). 107–117. 109 indexed citations
4.
Kerr, Barry D., Peter R. Flatt, & Victor A. Gault. (2010). Effects of γ-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1. Biochemical Pharmacology. 80(3). 396–401. 13 indexed citations
5.
Porter, David W., Barry D. Kerr, Peter R. Flatt, Christian Hölscher, & Victor A. Gault. (2010). Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary‐induced obesity and insulin resistance. Diabetes Obesity and Metabolism. 12(10). 891–899. 135 indexed citations
6.
Kerr, Barry D., Peter R. Flatt, & Victor A. Gault. (2010). (d-Ser2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Biochemical Pharmacology. 80(11). 1727–1735. 51 indexed citations
7.
Kerr, Barry D., et al.. (2010). Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide. Biochemical and Biophysical Research Communications. 404(3). 870–876. 21 indexed citations
8.
Kerr, Barry D., et al.. (2010). The glucagon-like peptide-1 agonist Liraglutide improves memory and learning in obese-diabetic mice. Regulatory Peptides. 164(1). 40–40.
9.
Kerr, Barry D., Nigel Irwin, Finbarr O’Harte, et al.. (2009). Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochemical Pharmacology. 78(8). 1008–1016. 40 indexed citations
10.
Gault, Victor A., Barry D. Kerr, Nigel Irwin, & Peter R. Flatt. (2008). C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochemical Pharmacology. 75(12). 2325–2333. 27 indexed citations
11.
Kerr, Barry D., Nigel Irwin, Peter R. Flatt, & Victor A. Gault. (2008). Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance. Peptides. 30(2). 219–225. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter S. Griffin Breakdown of academic impact, for papers by Todd M. Suter Breakdown of academic impact, for papers by Carrie Wittmer Breakdown of academic impact, for papers by Guido Haschke Breakdown of academic impact, for papers by Holly E. Bates Breakdown of academic impact, for papers by Margaret Lautz Breakdown of academic impact, for papers by J.H. Moltz Breakdown of academic impact, for papers by M. Ghiglione Breakdown of academic impact, for papers by Junhui Tan Breakdown of academic impact, for papers by Sechiko Suga
Rankless by CCL
2026